TABLE 3.
Drug | EC50 (95% CL) | Emax/Top (95% CL) | Mutant/WT EC50 | |
---|---|---|---|---|
WT | CP55,940 | 12.6 nM (3.6–43.7) | 127% (109–145) | NA |
WIN55,212-2 | 36.7 nM (12.4–108.3) | 95% (87–116) | NA | |
D2.63176A | CP55,940 | 67 nM (17–259)* | 59% (48–71)* | 5.3* |
WIN55,212-2 | 231 nM (27–1912)* | 89% (60–118) | 6.3* | |
K373A | CP55,940 | 70 nM (5.6–870)* | 70% (44–100) | 5.6* |
WIN55,212-2 | 274 nM (61–1230)* | 83% (53–112) | 7.5* | |
D2.63176A-K373A | CP55,940 | 39.8 nM (10–153)* | 29% (23–35)* | 3.2* |
WIN55,212-2 | 561 nM (60–5193)* | 59% (38–81)* | 15.3* | |
D2.63K-K373D | CP55,940 | 38 nM (6.9–209) | 82% (73–93) | 3 |
WIN55,212-2 | 126 nM (26–607) | 79% (63–95) | 3.4 |
P < 0.05.